AgeX Therapeutics Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Joanne Hackett

Amministratore delegato

US$103.1k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	1.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's What AgeX Therapeutics, Inc.'s (NYSEMKT:AGE) Shareholder Ownership Structure Looks Like

Feb 09

Does AgeX Therapeutics' (NYSEMKT:AGE) Share Price Gain of 14% Match Its Business Performance?

Nov 20

AMMINISTRATORE DELEGATO

Joanne Hackett (44 yo)

less than a year

Mandato

US$103,065

Compensazione

Dr. Joanne M. Hackett, Ph D., served as Independent Director of AgeX Therapeutics, Inc. since December 29, 2021, served as its Independent Chairman of the Board since May 2022 until August 09, 2023 and ser...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Joanne Hackett	Interim CEO & Chairman of the Board	2.3yrs	US$103.07k	Nessun dato
Jean-Christophe Renondin	Independent Director	less than a year	Nessun dato	0% $ 0
Gregory Bailey	Independent Director	5.6yrs	US$49.01k	0% $ 0
Steven Mintz	Independent Director	less than a year	Nessun dato	0.13% $ 41.7k

1.4yrs

Durata media

59.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di AGE non è considerato esperto (durata media del mandato 1.4 anni), il che suggerisce un nuovo consiglio.

AgeX Therapeutics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee

Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023

AgeX Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

AgeX Therapeutics, Inc., Annual General Meeting, Dec 07, 2022

AgeX Therapeutics, Inc. Announces Board Changes

Less than half of directors are independent

Recent updates

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. (NYSEAM:AGE) from a group of shareholders in a reverse merger transaction.

AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee

Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023

AgeX Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Agex Therapeutics Provides Non-Compliance Update Related to Stock Holders Equity

AgeX Therapeutics Announces Appeal of NYSE American Determination

NYSE American to Suspend Trading Immediately in Agex Therapeutics and Commence Delisting Proceedings

Third quarter 2022 earnings released: US$0.064 loss per share (vs US$0.052 loss in 3Q 2021)

AgeX Therapeutics, Inc., Annual General Meeting, Dec 07, 2022

Second quarter 2022 earnings released: US$0.069 loss per share (vs US$0.065 loss in 2Q 2021)

AgeX Therapeutics, Inc. Announces Board Changes

First quarter 2022 earnings released: US$0.071 loss per share (vs US$0.053 loss in 1Q 2021)

Full year 2021 earnings released: US$0.23 loss per share (vs US$0.29 loss in FY 2020)

AgeX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 29, 2022

AgeX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 29, 2022

AgeX Therapeutics, Inc. announced that it expects to receive $13.16 million in funding from Juvenescence Ltd.

Less than half of directors are independent

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.067 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.065 loss per share (vs US$0.071 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.053 loss per share (vs US$0.085 loss in 1Q 2020)

Full year 2020 earnings released: US$0.29 loss per share (vs US$0.33 loss in FY 2019)

Agex Therapeutics to Collaborate with the Ohio State University to Generate Proof-Of-Concept Animal Data for Agex’s Brown Adipose Tissue (Bat) Cell Therapy Candidate for Diabetes and Obesity

Atlas Capital Group Ltd. entered into an agreement to acquire LifeMap Sciences Ltd from AgeX Therapeutics, Inc. (AMEX:AGE).

Here's What AgeX Therapeutics, Inc.'s (NYSEMKT:AGE) Shareholder Ownership Structure Looks Like

New 90-day high: US$2.06

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell 2000 Dynamic Index

New 90-day high: US$1.94

AgeX Therapeutics, Inc., Annual General Meeting, Dec 28, 2020

Does AgeX Therapeutics' (NYSEMKT:AGE) Share Price Gain of 14% Match Its Business Performance?

Third quarter 2020 earnings released: US$0.067 loss per share

New 90-day high: US$2.48

First half earnings released

New 90-day high - US$1.52